glp-1 and liver disease The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Glucagon-like peptide (GLP)-1 and GLP-2

Szybiak-Skora W, Cyna W, Lacka K

[DOI] [PubMed] [Google Scholar] 99.24-7 PressRelease Internet

What NAPQI does: Directly binds to and damages cellular proteins Depletes glutathione rapidly Generates oxidative stress which damages DNA Triggers cell death Damages mitochondria, disrupting energy production NAPQI crosses the placenta and depletes fetal brain glutathione at doses below those causing maternal liver toxicity

The impact of the gut microbiota on drug metabolism and clinical outcome

3 AusubelF.BrentR.KingstonR.MooreD.SeidmanJ

[9] [10] Mojsov luch para que se incluyera su nombre en las patentes, y el Hospital General de Massachusetts acab accediendo a modificar cuatro patentes para incluir su nombre